Erschienen in:
15.05.2020 | Letter to the Editor
Response to letter to the editor
verfasst von:
Dyda Dao, Forough Farrokhyar, Cynthia J. Beeler, Anna J. Najor, Philip Y. Sun, Christopher Moir, Michael B. Ishitani
Erschienen in:
Pediatric Surgery International
|
Ausgabe 7/2020
Einloggen, um Zugang zu erhalten
Excerpt
The progress and innovation in research lie in peer scrutiny and we welcome the opportunity to explain further the reasoning in our study design and analysis [
1]. We thank the authors for their insight and recommendations. Prospective randomized trials are unwarranted, considering that complete excision is the established treatment modality. Prospective studies with observational design are, however, lacking but may be unfeasible with rare diseases [
2]. Therefore, this brings up the need for a validated and prospectively maintained database or registry for lipoblastoma (LB) and lipoblastomatosis (LBM). …